Summary
In 1H, revenue rose +11.5% but operating income fell -1.5%, so top-line growth did not translate into profit growth. The main drag was lower profit in the Digital Certification & Seal Business. In 3Q, we will look for two things. First, whether the system development cost increase, which management called temporary, has run its course. Second, whether revenue growth at GMO Sign and GMO Trust Login is starting to lift segment profit. Management expects revenue delayed from a large overseas customer to be booked mainly in 4Q. 3Q will therefore show underlying profitability without that catch-up. The consolidation scope is also changing: GMO Digital Lab is deconsolidated while GMO AI Connect's P&L is consolidated for the first time. In addition, a JPY 440M gain on the sale of subsidiary shares will be booked as extraordinary income, so reported and underlying figures must be assessed separately. The key focus areas for 3Q results are whether the net income plan, raised on October 19, is credible and how the company will reach its unchanged operating income target of JPY 1,622M.
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
Segment ProfitabilityYoY change in Digital Certification & Seal Business segment profit | In 1H, segment revenue grew +10.1% but profit fell to JPY 428M (-19.9%). Whether one-off costs have peaked, together with recovery of delayed revenue in 4Q, will determine the full-year profit level. |
Profit Progress9M operating income progress vs. full-year plan and standalone 3Q operating income | 1H progress was 36.1%, below 40.2% a year earlier (vs. full-year actual). Growth over the prior-year 3Q figure of JPY 390M will be a test of the 2H plan (+17.6% vs. prior-year 2H, our estimate). |
Extraordinary Items & Revised PlanGain on sale of subsidiary shares and progress vs. the raised net income plan | Extraordinary income of JPY 440M is expected in 3Q. The net income plan has been raised from JPY 1,052M to JPY 1,312M. Progress at the recurring profit level, excluding the gain, should be tracked separately. |
Change in Consolidation ScopeDX Business revenue/profit and contribution from GMO AI Connect | With GMO Digital Lab deconsolidated, DX Business YoY figures are not like-for-like. The P&L impact of the new consolidation and goodwill amortization needs to be isolated. |
Growth BusinessCloud Infrastructure Business segment profit and CloudCREW expansion | 1H segment profit was JPY 144M (+34.9%). We will check whether profit growth continues into 3Q, supported by the strategic collaboration with AWS. |
Key Issues from Previous Results (FY12/2026 2Q Results)
In 1H, revenue reached JPY 11,091M (+11.5%) and recurring profit JPY 632M (+9.4%). However, operating income was only JPY 585M (-1.5%), and progress vs. the full-year plan was just 36.1%, making the plan more 2H-weighted. 3Q requires separate assessment of three factors: the Digital Certification profit recovery, the change in consolidation scope, and the booking of extraordinary income.
1. Profit Recovery in the Digital Certification & Seal Business
- Previous Period: Segment revenue was JPY 6,937M (+10.1%), but segment profit fell to JPY 428M (-19.9%).
- Previous Period: Management attributed the decline to delayed revenue from a large overseas customer (long-term contract) and a temporary rise in system development costs.
- Previous Period: Key products remained strong. GMO Sign delivered higher revenue and profit, and GMO Trust Login continued to win large customers.
- This Quarter: Check whether system development costs, described as temporary, have normalized in 3Q.
- This Quarter: The delayed revenue is expected mainly in 4Q and is not a 3Q item. 3Q results should confirm that the 4Q booking outlook is maintained.
- This Quarter: Key focus is whether price optimization and new large-customer wins start to show in 3Q margins.
- Key Metrics: YoY change in 9M segment profit and segment margin (1H: 6.2% vs. 8.5% a year earlier, our estimate).
2. Progress of Consolidated Operating Income vs. Full-Year Plan and Credibility of the 2H Weighting
- Previous Period: Standalone 2Q operating income was JPY 155M, down from JPY 430M in 1Q (our estimate).
- Previous Period: Gross profit margin was 56.8%, down from 59.0% a year earlier.
- Previous Period: The SG&A-to-revenue ratio improved to 51.6% from 53.1% a year earlier (our estimate). The main issue is therefore the rising cost of sales burden.
- This Quarter: Achieving the full-year operating income plan of JPY 1,622M requires JPY 1,037M in 2H (our estimate). This is +17.6% vs. JPY 882M in the prior-year 2H.
- This Quarter: Only net income was revised upward. The 3Q earnings release should clarify whether revenue, operating income, and recurring profit targets have changed.
- Key Metrics: 9M operating income progress vs. full-year plan (prior year: 66.6% vs. full-year actual) and standalone 3Q operating income vs. JPY 390M a year earlier.
3. Gain on Sale of Subsidiary Shares and the Raised Net Income Plan
- Previous Period: Interim net income rose +18.6%, outpacing the +9.4% increase in recurring profit.
- Previous Period: The main driver was a lower tax burden from an income tax adjustment of JPY -113M. Meanwhile, business restructuring costs of JPY 17M, covering special severance at an overseas subsidiary, were booked as an extraordinary loss.
- This Quarter: The sale of GMO Digital Lab shares is expected to generate JPY 440M of extraordinary income in 3Q. The sale price includes additional consideration under an earn-out clause, so we will check whether the booked amount matches expectations.
- This Quarter: On October 19, the company raised its net income plan to JPY 1,312M, reflecting the gain on sale and FX gains. We will check how much FX gain was booked in non-operating income.
- Key Metrics: 9M extraordinary income and progress vs. the revised net income plan of JPY 1,312M (37.3% at 1H, our estimate).
- Key Metrics: Breakdown of extraordinary items and income taxes.
4. Impact of the Change in Consolidation Scope
- Previous Period: DX Business revenue was JPY 532M (+20.1%), and the segment loss narrowed to JPY 4M from JPY 58M a year earlier. Order wins at GMO Digital Pay drove the improvement.
- Previous Period: GMO Digital Lab was deconsolidated from the 3Q accounting period. GMO AI Connect's income statement is consolidated from July 2026.
- Previous Period: The acquisition cost of GMO AI Connect was JPY 563M, with provisional goodwill of JPY 331M amortized straight-line over eight years.
- This Quarter: Reported DX Business figures are not comparable on a like-for-like basis. The revenue loss from deconsolidation must be separated from the benefit of concentrating headcount on AI-related services.
- This Quarter: Goodwill amortization will be roughly JPY 10M per quarter (our estimate). Note that goodwill may change once the purchase price allocation is finalized.
- Key Metrics: 9M DX Business revenue and segment profit/loss, and management commentary on the change in consolidation scope.
5. CloudCREW Expansion in the Cloud Infrastructure Business
- Previous Period: Segment revenue rose to JPY 3,917M (+12.8%) and segment profit to JPY 144M (+34.9%).
- Previous Period: On July 1, 2026, the company signed a strategic collaboration agreement with AWS to support cloud adoption by mid-sized companies and SMEs.
- This Quarter: Legacy hosting revenue is holding flat YoY. We want to see whether the shift toward high-margin cloud products is showing up in margins.
- This Quarter: Key focus is whether deal wins leveraging AWS support programs and co-investment resources have begun.
- Key Metrics: YoY change in 9M segment profit and segment margin (1H: 3.7% vs. 3.1% a year earlier, our estimate).
Key Timely Disclosures This Quarter
- 2026/10/19Notice Regarding Revision of Full-Year Guidance (Upward) and Dividend Forecast (Increase) - The net income plan was raised from JPY 1,052M to JPY 1,312M, reflecting the gain on sale of subsidiary shares and FX gains. The year-end dividend forecast was also raised from JPY 59.67 to JPY 74.35, signaling a proactive stance on shareholder returns.
- 2026/10/13[Nation's First] Yamanashi Prefecture and All 27 Municipalities Jointly Procure E-Contracts - A large public-sector deal in which the prefecture and all of its municipalities adopt GMO Sign together. It could serve as a template for rollout to other local governments. As the disclosure came after the 3Q period end, any P&L contribution should be checked from 4Q onward.
- 2026/10/09GMO GlobalSign Holdings K.K. Signs Strategic Collaboration Agreement (SCA) with AWS - The initiative expands DX support for mid-sized companies and SMEs by offering generative AI adoption, cloud migration, and operations and maintenance as an integrated package. It underpins CloudCREW's medium-term growth, and the timing of earnings contribution will be tracked in upcoming results.
Previous Quarter Results (FY12/2026 2Q Actual)
The company operates three segments: the Digital Certification & Seal Business, the Cloud Infrastructure Business, and the DX Business. Under its long-term vision, "Designing Trust, Connecting the World.", it aims to become the "infrastructure of trust" that secures the AI agent era. In 1H, its three key products, GMO Sign, GMO Trust Login, and CloudCREW, sustained high growth and delivered double-digit revenue growth. However, operating income was flat YoY due to delayed revenue and temporary cost increases in the Digital Certification business. The full-year plan (revenue of JPY 22,286M, operating income of JPY 1,622M) was left unchanged at 2Q results, leaving profits weighted toward 2H.
| Item | Amount | YoY | vs. Company Plan | Notes |
|---|---|---|---|---|
| Revenue | JPY 11,091M | +11.5% | - | High growth in key products drove revenue. Progress vs. full-year plan: 49.8% (our estimate) |
| Operating Income | JPY 585M | -1.5% | - | Weighed down by delayed Digital Certification revenue and higher system development costs. Gross profit margin: 56.8% (prior year: 59.0%) |
| Recurring Profit | JPY 632M | +9.4% | - | Absence of the prior-year FX loss of JPY 64M |
| Interim Net Income Attributable to Owners of Parent Company | JPY 490M | +18.6% | - | Boosted by an income tax adjustment of JPY -113M. Business restructuring costs of JPY 17M booked as an extraordinary loss |
| EPS | JPY 42.75 | +18.7% | - | Full-year forecast: JPY 91.79 (as of 2Q results) |
Progress vs. Full-Year Plan (Recurring Profit Basis): 39.8% (prior year: 40.2%) *Progress rates are our estimates. The prior-year figure is relative to the FY12/2025 full-year actual of JPY 1,435M.
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.